Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium Academic Article uri icon


MeSH Major

  • Carcinoma, Transitional Cell
  • Colony-Stimulating Factors
  • Urogenital Neoplasms


  • Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered at a dose of 1-60 micrograms/kg of body weight to 22 patients with transitional cell carcinoma before chemotherapy as part of a Phase I/II study. In all patients, a specific dose-dependent increase in the absolute neutrophil count (ANC) of 1.8-12 fold was seen. In addition, this augmentation in the ANC was accompanied by an increase in leukocyte alkaline phosphatase, a marker of secondary granule formation. In six of eight patients analyzed, an increase in bone marrow myeloid to erythroid cell ratio was seen. Day 14 peripheral blood cell derived colony forming unit granulocyte macrophage were also increased by day 6 of rhG-CSF treatment. Circulating levels of eosinophils and basophils were unchanged; however, a 10-fold increase in monocytes was observed in patients treated at the highest doses. There was also a small increase in CD3+ lymphocytes that was not dose dependent. Hemoglobin, hematocrit, and platelet count remained near baseline throughout the period of rhG-CSF administration. These findings demonstrate that rhG-CSF is a potent stimulus for normal neutrophil proliferation and maturation.

publication date

  • January 1988



  • Academic Article



  • eng

PubMed Central ID

  • PMC442704

PubMed ID

  • 2459163

Additional Document Info

start page

  • 1454

end page

  • 61


  • 82


  • 4